NIAID 50th Anniversary Symposium

May 28, 1998

Did you know that nearly 5 percent of adults in North America suffer from autoimmune diseases such as multiple sclerosis, diabetes, arthritis and lupus?

You are invited to attend a symposium highlighting groundbreaking research being conducted in developing vaccines for these diseases. The symposium will feature leading academic and industry investigators in immunology and autoimmune diseases discussing their current research, and the outlook for using vaccines to prevent and treat these diseases in the future.

The symposium celebrates the 50th anniversary of the National Institute of Allergy and Infectious Diseases (NIAID) and is being held in partnership with the Juvenile Diabetes Foundation International, numerous other components of the National Institutes of Health (NIH) and several autoimmune disease organizations.

Classically, a vaccine turns on specific immune responses that prevent a particular infectious disease. More recently, however, scientists have begun investigating how vaccines might also be designed to turn off specific undesirable immune responses that are directed against normal, healthy tissues and result in autoimmune diseases. A variety of approaches to inducing tolerance to target antigens in these healthy tissues or of otherwise modulating these destructive immune responses have been successful in animal models of human autoimmune diseases. Clinical trials in humans are currently being conducted with several agents. Scientists hope that these new approaches may lead to more effective interventions to prevent and treat autoimmune diseases.

The meeting takes place all day Monday, June 8 (see attached agenda) at the Natcher Conference Center Auditorium (Bldg. 45) on the main NIH campus in Bethesda, Md. No registration is required. Because parking is limited, attendees are encouraged to use Metro. The Medical Center Metro Station is within walking distance of the Natcher Conference Center.

For more information, please call the NIAID Office of Communications at (301) 402-1663.

Natcher Conference Center Auditorium
45 Center Drive
National Institute of Health
Bethesda, MD

June 8, 1998



8:20 AM - A Plan for Vaccination Against Disease
(Charles Janeway, M.D., Yale University)

9:10 AM - CD40 As a Central Mediator in Cellular and Humoral Immunity
(Randolph J. Noelle, Ph.D., Dartmouth Medical School)

10:00 AM - BREAK

10:20 AM - Mapping Autoantigenic T Cell Epitopes to Prevent Juvenile Diabetes
(Hugh McDevitt, M.D., Stanford University)

11:10 AM - Pathways: Immunologic Vaccination for the Prevention of Type Diabetes
(George Eisenbarth, M.D., Ph.D., University of Colorado)


1:30 PM - Spontaneously Developing Arthritis in a TCR Transgenic Model
(Diane Mathis, Ph.D., INSERM/Strasbourg)

2:20 PM - Vaccines for Prevention and Treatment of Rheumatoid Arthritis
(Dennis A. Carson, M.D., University of California-SD)

3:10 PM - BREAK

3:30 PM - Treatment of Autoimmune Diseases with MHC-Based Therapeutics
(Maureen Howard, Ph.D., Anergen)

4:20 PM - Antigen-Specific Immunotherapy in Autoimmune Disease
(David Hafler, M.D., Harvard Medical School)

National Institute of Allergy and Infectious Diseases
National Institute of Diabetes and Digestive and Kidney Diseases
National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Institute of Child Health and Human Development
National Eye Institute
National Institute of Dental Research
National Institute of Neurologic Disorders and Stroke
National Heart, Lung and Blood Institute
Office of Research on Women's Health, National Institutes of Health
Juvenile Diabetes Foundation International
American Autoimmune Related Diseases Association
Lupus Foundation of America
National Multiple Sclerosis Society
Arthritis Foundation
The S.L.E. Foundation

NIH/National Institute of Allergy and Infectious Diseases

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to